Detalles de la búsqueda
1.
TransCon IL-2 ß/γ: a novel long-acting prodrug with sustained release of an IL-2Rß/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
J Immunother Cancer
; 10(7)2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35817480
2.
Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism.
J Bone Miner Res
; 34(11): 2075-2086, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31291476
Resultados
1 -
2
de 2
1
Próxima >
>>